Anthrax – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Anthrax – Drugs In Development, 2024 report and make more profitable business decisions.
Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe bloody diarrhea in the later stages of the disease, sore throat, and difficulty swallowing. Risk factors include illegal intravenous drug use, exposure to animal skins, and working in veterinary medicine, especially dealing with livestock.
The Anthrax drugs in development market research report provide comprehensive information on the therapeutics under development for Anthrax, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anthrax and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Anthrax | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 28 molecules, with 21 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Anthrax therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Anthrax pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Anthrax treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbVacc IncAphios Corp
Biologics Resources LLC
BlueWillow Biologics Inc
Crestone Inc
Dynavax Technologies Corp
GC Biopharma Corp
Greffex Inc
Hawaii Biotech Inc
iBio Inc
iNtRON Biotechnology Inc
Israel Institute of Technology
NovoBiotic Pharmaceuticals LLC
Opal Biosciences Ltd
Paratek Pharmaceuticals Inc
Protein Potential LLC
ProThera Biologics Inc
Texas Tech University Health Sciences Center
The National Institute of Allergy and Infectious Diseases
U.S. Air Force Academy
University of South Florida
University of Texas Medical Branch at Galveston
Vanderbilt University
Venomyx Inc
VLP Biotech Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Anthrax reports